重症COVID-19患者的出血、弥散性血管内凝血与血栓并发症:国际COVID-19重症监护联盟研究
该前瞻性观察研究纳入32个国家229个ICU中2020年1月1日至2021年12月31日收治的成年重症COVID-19患者,评估出血、弥散性血管内凝血和血栓(HECTOR)并发症的患病率及结局。11,969例合格患者中1,732例(14%)发生HECTOR并发症,其中急性血栓1,249例(10%),出血并发症579例(4.8%),弥散性血管内凝血11例(0.09%)。生存者中,有HECTOR者的ICU停留时间更长(中位数19天 vs 12天,p<0.001),但总体ICU死亡风险相似(HR 1.01;95%CI 0.92-1.12;p=0.784);非ECMO患者中风险升高(HR 1.13;95%CI 1.02-1.25;p=0.015)。出血并发症与ICU死亡风险升高相关(HR 1.26;95%CI 1.09-1.45;p=0.002),血栓并发症与风险降低相关(HR 0.88;95%CI 0.79-0.99;p=0.03)。
要点
- 重症COVID-19 ICU患者HECTOR并发症总发生率为14%(1,732/11,969),其中急性血栓10%、出血4.8%、弥散性血管内凝血0.09%。
- 出血并发症与ICU死亡风险升高相关(HR 1.26;95%CI 1.09-1.45;p=0.002),血栓并发症与风险降低相关(HR 0.88;95%CI 0.79-0.99;p=0.03)。
- 接受ECMO的患者是出血并发症的特别高风险人群,ECMO使用为HECTOR危险因素(单因素分析)。
- 生存者中有HECTOR者ICU停留时间更长(中位数19天 vs 12天;p<0.001)。
- 总体ICU死亡风险相似(HR 1.01;95%CI 0.92-1.12;p=0.784),但非ECMO患者中风险升高(HR 1.13;95%CI 1.02-1.25;p=0.015)。
适用人群与场景
- 2020年1月1日至2021年12月31日入住参与ICU的成年患者(≥16岁),因重症COVID-19接受治疗。
- 研究纳入32个国家229个ICU的前瞻性观察队列。
研究设计与关键结果
- 研究设计:前瞻性观察研究,纳入32个国家229个ICU的11,969例合格重症COVID-19成年患者。
- HECTOR并发症发生于1,732/11,969例(14%)。
- 急性血栓1,249例(10%):肺栓塞712例(57%)、心肌缺血413例(33%)、深静脉血栓93例(7.4%)、缺血性卒中49例(3.9%)。
- 出血并发症579例(4.8%):胃肠道出血276例(48%)、出血性卒中83例(14%)、肺出血77例(13%)、ECMO插管部位相关出血68例(12%)。
- 弥散性血管内凝血11例(0.09%)。
- 单因素分析显示糖尿病、心脏病、肾脏疾病及ECMO使用为HECTOR危险因素。
- 生存者中有HECTOR者ICU停留时间更长(中位数19天 vs 12天;p<0.001)。
- 总体ICU死亡风险相似(HR 1.01;95%CI 0.92-1.12;p=0.784);非ECMO患者中风险升高(HR 1.13;95%CI 1.02-1.25;p=0.015)。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为HECTOR事件是ICU重症COVID-19患者的常见并发症(14%)。
- 作者认为接受ECMO的患者出血并发症风险特别高。
- 作者认为出血并发症(而非血栓并发症)与ICU死亡率升高相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the prevalence and outcomes associated with hemorrhage, disseminated intravascular coagulopathy, and thrombosis (HECTOR) complications in ICU patients with COVID-19.
DESIGN: Prospective, observational study.
SETTING: Two hundred twenty-nine ICUs across 32 countries.
PATIENTS: Adult patients (≥ 16 yr) admitted to participating ICUs for severe COVID-19 from January 1, 2020, to December 31, 2021.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: HECTOR complications occurred in 1,732 of 11,969 study eligible patients (14%). Acute thrombosis occurred in 1,249 patients (10%), including 712 (57%) with pulmonary embolism, 413 (33%) with myocardial ischemia, 93 (7.4%) with deep vein thrombosis, and 49 (3.9%) with ischemic strokes. Hemorrhagic complications were reported in 579 patients (4.8%), including 276 (48%) with gastrointestinal hemorrhage, 83 (14%) with hemorrhagic stroke, 77 (13%) with pulmonary hemorrhage, and 68 (12%) with hemorrhage associated with extracorporeal membrane oxygenation (ECMO) cannula site. Disseminated intravascular coagulation occurred in 11 patients (0.09%). Univariate analysis showed that diabetes, cardiac and kidney diseases, and ECMO use were risk factors for HECTOR. Among survivors, ICU stay was longer (median days 19 vs 12; p < 0.001) for patients with versus without HECTOR, but the hazard of ICU mortality was similar (hazard ratio [HR] 1.01; 95% CI 0.92-1.12; p = 0.784) overall, although this hazard was identified when non-ECMO patients were considered (HR 1.13; 95% CI 1.02-1.25; p = 0.015). Hemorrhagic complications were associated with an increased hazard of ICU mortality compared to patients without HECTOR complications (HR 1.26; 95% CI 1.09-1.45; p = 0.002), whereas thrombosis complications were associated with reduced hazard (HR 0.88; 95% CI 0.79-0.99, p = 0.03).
CONCLUSIONS: HECTOR events are frequent complications of severe COVID-19 in ICU patients. Patients receiving ECMO are at particular risk of hemorrhagic complications. Hemorrhagic, but not thrombotic complications, are associated with increased ICU mortality.
参考来源
- Fanning JP, Weaver N, Fanning RB, et al. Hemorrhage, Disseminated Intravascular Coagulopathy, and Thrombosis Complications Among Critically Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study. Crit Care Med. 2023. PMID: 36867727. doi:10.1097/CCM.0000000000005798
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。